Drug Trial Radar · NCT07758920
A Clinical Trial to Evaluate the Efficacy and Safety of HL-1186 Tablet in the Treatment of Postherpetic Neuralgia
Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Aug 2026
Primary completion
Jun 2027
Study completion Jun 2027
Sponsor
- Lead sponsor
- Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 11, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled, parallel-group trial to evaluate the safety, efficacy and pharmacokinetic (PK) profile of HL-1186 Tablet in patients with postherpetic neuralgia (PHN).
Conditions
- Postherpetic Neuralgia ( PHN )
Interventions
HL-1186Drug
HL-1186 tablet for oral administration
HL-1186 placeboDrug
HL-1186 placebo tablet for oral administration
Pregabalin capsuleDrug
Pregabalin capsule for oral administration
Pregabalin capsule placeboDrug
Pregabalin capsule placebo for oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in the Average Daily Pain Score (ADPS) from baseline after 12 weeks of administrationTime frame: Day 1 to Day 84
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.